We looked at outcomes of patients receiving allogeneic hematopoietic stem cell transplant with post-transplant cyclophosphamide-based GvHD prophylaxis, including matched sibling donors and haploidentical donors. And we wanted to look at if there is any difference in outcomes with these two donor sources when we are using post-transplant cyclophosphamide for GvHD prophylaxis. And we did not find significant differences in terms of overall survival, disease-free survival, relapse, acute and chronic graft-versus-host disease...
We looked at outcomes of patients receiving allogeneic hematopoietic stem cell transplant with post-transplant cyclophosphamide-based GvHD prophylaxis, including matched sibling donors and haploidentical donors. And we wanted to look at if there is any difference in outcomes with these two donor sources when we are using post-transplant cyclophosphamide for GvHD prophylaxis. And we did not find significant differences in terms of overall survival, disease-free survival, relapse, acute and chronic graft-versus-host disease. The patients receiving haploidentical transplant had a slightly higher risk of non-relapse mortality compared to matched sibling donors, but that did not impact the overall survival. We did identify several factors that correlate with survival with either donor source and these include patient recipient and donor age, their comorbidities, other medical conditions, their performance status, the CMV serostatus. These were some of the risk factors that were identified. So we will explore further in this and we hope to publish these findings soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
